XNAS · Healthcare · Biotechnology
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | Q1 2026 | -0.36 | -0.32 | +11.11% | $0 | ✅ Beat | +2.50% | -1.67% | — |
| 2026-03-11 | Q4 2025 | -0.40 | -0.38 | +5.00% | $0 | ✅ Beat | -1.91% | -3.76% | -3.76% |
| 2025-11-06 |
| Q3 2025 |
| -0.53 |
| -0.43 |
| +18.87% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-03-03 | Q4 2024 | -0.98 | -0.82 | +16.33% | $0 | ✅ Beat | -2.17% | +3.62% | +2.17% |
| 2024-11-07 | Q3 2024 | -0.98 | -0.95 | +3.06% | $0 | ✅ Beat | -1.25% | -15.40% | -2.24% |
| 2024-08-07 | Q2 2024 | -0.85 | -0.92 | -8.24% | $0 | ❌ Miss | -2.23% | -4.86% | +2.63% |
| 2023-08-09 | Q2 2023 | -0.71 | -0.70 | +1.41% | $248,000 | ✅ Beat | +3.30% | -5.39% | -9.52% |
| 2023-05-09 | Q1 2023 | -0.67 | -0.67 | +0.00% | $1.3M | ➖ Inline | +2.31% | -1.38% | +1.16% |
Showing last 8 quarters.